This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus

This study has been terminated.
(change in the business strategy of the sponsor)
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01129778
First received: May 21, 2010
Last updated: June 2, 2017
Last verified: June 2017
Results First Received: January 7, 2017  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Treatment
Conditions: Barrett Esophagus
Gastroesophageal Reflux
Interventions: Drug: Zegerid (proton pump inhibitor)
Procedure: Bravo pH monitoring

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
5 participants withdrew after providing their informed consent and before beginning their participation in the study.

Reporting Groups
  Description
Received Zegerid (Ome-NaBic) Ome-NaBic 40 mg orally 1 h before breakfast and bedtime for up to 29 days

Participant Flow:   Overall Study
    Received Zegerid (Ome-NaBic)
STARTED   22 
COMPLETED   15 
NOT COMPLETED   7 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
21 participants who underwent pH testing were evaluable for Baseline Characteristics.

Reporting Groups
  Description
Received Zegerid (Ome-NaBic) Ome-NaBic 40 mg orally 1 h before breakfast and bedtime for up to 29 days

Baseline Measures
   Received Zegerid (Ome-NaBic) 
Overall Participants Analyzed 
[Units: Participants]
 21 
Age 
[Units: Years]
Mean (Standard Deviation)
 61  (10) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      4  19.0% 
Male      17  81.0% 
Mean RDQ heartburn score [1] 
[Units: Units on a scale]
Mean (Standard Deviation)
 10  (6) 
[1] The RDQ is a 12 item survey that asks the patient to rate the frequency and severity of GERD symptoms. Each item is scored from 0 to 5 where a score of 0 is equivalent to an asymptomatic state and 5 indicates the worst severity of GERD symptoms. The total RDQ is a sum of all 12 items, and can range from 0 to 60.


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Time Esophageal pH< 4   [ Time Frame: Days 1 and 2 ]

2.  Secondary:   Reflux Disease Questionnaire Score on Day 1 After Therapy Completion   [ Time Frame: Day 1 after therapy period completion ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The limitations included the small sample size, a cohort of patients with primarily short-segment BE, and the fact that the study relied on comparison of intraoesophageal pH levels on Ome-NaBic to other PPIs based on historical controls.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: W. Ray Kim, MD, Chief of Gastroenterology and Hepatology
Organization: Stanford University
phone: 650-725-6511
e-mail: wrkim@stanford.edu



Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01129778     History of Changes
Other Study ID Numbers: SU-04302010-5803
Study First Received: May 21, 2010
Results First Received: January 7, 2017
Last Updated: June 2, 2017